Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 23, 2021, titled "Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended‐Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity".